GAMMA Investing LLC Raises Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

GAMMA Investing LLC lifted its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 27,448.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 387,331 shares of the medical research company's stock after purchasing an additional 385,925 shares during the quarter. GAMMA Investing LLC owned 0.22% of IQVIA worth $68,286,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Versant Capital Management Inc grew its stake in shares of IQVIA by 129.5% during the 1st quarter. Versant Capital Management Inc now owns 677 shares of the medical research company's stock valued at $119,000 after purchasing an additional 382 shares during the period. Legacy Wealth Management LLC MS purchased a new position in shares of IQVIA during the 1st quarter valued at about $3,425,000. Wellington Management Group LLP lifted its position in shares of IQVIA by 12.7% during the 4th quarter. Wellington Management Group LLP now owns 9,791 shares of the medical research company's stock valued at $1,924,000 after buying an additional 1,106 shares in the last quarter. Fairtree Asset Management Pty Ltd purchased a new position in shares of IQVIA during the 4th quarter valued at about $503,000. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of IQVIA by 83.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 9,861 shares of the medical research company's stock valued at $1,938,000 after buying an additional 4,483 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Trading Up 3.5%

IQVIA stock traded up $5.02 during mid-day trading on Wednesday, hitting $147.80. The company's stock had a trading volume of 2,684,601 shares, compared to its average volume of 1,581,870. The company has a 50 day moving average of $149.24 and a 200-day moving average of $179.93. The stock has a market cap of $25.57 billion, a PE ratio of 19.71, a P/E/G ratio of 1.99 and a beta of 1.28. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. During the same period in the prior year, the business earned $2.54 EPS. The business's revenue for the quarter was up 2.5% compared to the same quarter last year. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Truist Financial lowered their price target on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. Morgan Stanley upped their price objective on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Wall Street Zen cut IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Finally, JPMorgan Chase & Co. decreased their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $226.32.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.